Physician profile
Mark A Hardin
NPI 1770544777
$2,319.64
in general payments reported to CMS, 2019-2025
28 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $441 · 2021: $300 · 2022: $246 · 2023: $99.91 · 2024: $160 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $404.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $315.73 | 2019-2022 | |
| Abbott Laboratories | $207.19 | 2023-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $203.49 | 2019-2022 | |
| Allergan, INC. | $157.86 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $156.65 | 2019-2020 | |
| Stryker Corporation | $144.90 | 2025 | Na |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $120.51 | 2019 | |
| Abbvie INC. | $100.07 | 2021-2023 | |
| Venclose INC. | $97.59 | 2020 | |
| Medtronic Vascular, INC. | $95.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $82.99 | 2020-2022 | |
| Eisai INC. | $55.37 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $51.94 | 2020-2023 | Farxiga |
| Melinta Therapeutics, LLC | $47.79 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.16 | 2021 | |
| Pfizer INC. | $37.58 | 2020-2022 | |
| Amarin Pharma, INC. | $36.47 | 2020-2021 | |
| Amgen INC. | $36.27 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $35.31 | 2019 | |
| Glaxosmithkline, LLC. | $29.41 | 2019 | |
| Lilly USA, LLC | $27.01 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $23.65 | 2021 | |
| Heartflow, INC. | $22.43 | 2023 | Ffrct |
| Edwards Lifesciences Corporation | $19.13 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.